211. Do clinically equivalent dosing ratios exist between different formulations of botulinum neurotoxin A in the treatment of adult spasticity, dystonia, blepharospasm, and hemifacial spasm: A systematic review

Toxicon ◽  
2015 ◽  
Vol 93 ◽  
pp. S66 ◽  
Author(s):  
Younan Zhang ◽  
Karen Coulton ◽  
Raymond Rosales ◽  
Austen P. Moore ◽  
Melanie Plested
Keyword(s):  
Systematic Review ◽  
Hemifacial Spasm ◽  
Botulinum Neurotoxin ◽  
Botulinum Neurotoxin A

scholarly journals Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Ren-Wen Ho ◽  
Po-Chiung Fang ◽  
Tsai-Ling Chao ◽  
Chun-Chih Chien ◽  
Ming-Tse Kuo
Keyword(s):  
Hemifacial Spasm ◽  
Botulinum Neurotoxin ◽  
Botulinum Neurotoxin A

scholarly journals Botulinum Neurotoxin A Intravesical Injections in Interstitial Cystitis/Bladder Painful Syndrome: A Systematic Review with Meta-Analysis

Toxins ◽  
2019 ◽  
Vol 11 (9) ◽  
pp. 510 ◽  
Author(s):  
Antonella Giannantoni ◽  
Marilena Gubbiotti ◽  
Vittorio Bini
Keyword(s):  
Systematic Review ◽  
Interstitial Cystitis ◽  
Effect Size ◽  
Botulinum Neurotoxin ◽  
Meta Analysis ◽  
Medium Effect ◽  
Controlled Trials ◽  
Botulinum Neurotoxin A ◽  
Painful Syndrome ◽  
Medium Effect Size

Botulinum neurotoxin A (BoNT/A) appears to be one of the best intravesical treatments for interstitial cystitis/bladder painful syndrome (IC/BPS). We aimed to point out what the evidence is regarding the effects of BoNT/A intravesically injected in patients with IC/BPS. We performed a systematic review of all randomized controlled trials (RCTs) assessing BoNT/A for IC/BPS by using Medline, EMBASE, CINAHL, CENTRAL and MetaRegister of Controlled Trials. Standardized mean differences (SMD) were extracted from the available trials and combined in a meta-analysis applying a random effect model, including heterogeneity of effects. Twelve trials were identified. Significant benefits from BoNT/A injections were detected in: Interstitial Cystitis Symptom Index and Problem Index (ICSI, ICPI) (small to medium effect size: SMD = –0.302; p = 0.007 and –0.430, p = 0.004, respectively); Visual Analog Scale (VAS) for pain and day-time urinary frequency (medium effect size: SMD = –0.576, p < 0.0001 and –0.546, p = 0.013, respectively). A great effect size was detected for post-void residual volume (PVR, SMD = 0.728; p =0.002) although no clinically relevant in most cases. Great heterogeneity was observed in treatments’ methodologies and symptoms assessment. Overall, BoNT/A intravesical injections significantly improve some of the most relevant symptoms affecting IC/BPS patients.

Identification of novel inhibitors of botulinum neurotoxin A

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
C Yalamanchili ◽  
VK Manda ◽  
AG Chittiboyina ◽  
WA Harrell Jr ◽  
RP Webb ◽  
...  
Keyword(s):  
Botulinum Neurotoxin ◽  
Botulinum Neurotoxin A

Botulinumtoxin zur Behandlung von neuropathischen Schmerzen

2017 ◽  
Vol 36 (05) ◽  
pp. 315-323
Author(s):  
N. Üçeyler ◽  
C. Sommer
Keyword(s):  
Botulinum Neurotoxin ◽  
Neuropathische Schmerzen ◽  
Botulinum Neurotoxin A ◽  
Topische Therapien

ZusammenfassungDie Behandlung neuropathischer Schmerzen mit systemisch wirksamen oral verabreichten Pharmaka ist bei vielen Patienten wirksam, kann jedoch zu zentralnervösen unerwünschten Wirkungen wie Müdigkeit oder Schwindel führen. Daher sind in den letzten Jahren topische Therapien in das Zentrum der Aufmerksamkeit gerückt. Botulinumtoxin, etabliert in der Therapie von Dystonien und Spastik, wurde zunehmend bei Schmerzerkrankungen getestet, hierbei ist Botulinum-Neurotoxin A der am besten untersuchte Serotyp. Die häufigsten Indikationen waren Schmerzen im Trigeminusversorgungsbereich und periphere neuropathische Schmerzen. Bei den meisten Studien war Botulinum-Neurotoxin A Placebo deutlich überlegen. Präklinische Studien zum Wirkmechanismus erbrachten die Erkenntnis, dass neben dem erwarteten peripheren Effekt sehr wahrscheinlich auch eine zentrale Reduktion der Ausschüttung von exzitatorischen Neurotransmittern an der Wirkung beteiligt ist.

scholarly journals Primary Cultures of Embryonic Chicken Neurons for Sensitive Cell-Based Assay of Botulinum Neurotoxin: Implications for Therapeutic Discovery

2007 ◽  
Vol 12 (3) ◽  
pp. 370-377 ◽  
Author(s):  
Andrea M. Stahl ◽  
Gordon Ruthel ◽  
Edna Torres-Melendez ◽  
Tara A. Kenny ◽  
Rekha G. Panchal ◽  
...  
Keyword(s):  
Nervous System ◽  
Botulinum Toxin ◽  
Neutralizing Antibodies ◽  
Botulinum Neurotoxin ◽  
Potent Inhibitor ◽  
Primary Cultures ◽  
Embryonic Chick ◽  
Sensitive Cell ◽  
Botulinum Neurotoxin A ◽  
Therapeutic Compounds

Botulinum toxin is an exceedingly potent inhibitor of neurotransmission across the neuromuscular junction, causing flaccid paralysis and death. The potential for misuse of this deadly poison as a bioweapon has added a greater urgency to the search for effective therapeutics. The development of sensitive and efficient cell-based assays for the evaluation of toxin antagonists is crucial to the rapid and successful identification of therapeutic compounds. The authors evaluated the sensitivity of primary cultures from 4 distinct regions of the embryonic chick nervous system to botulinum neurotoxin A (BoNT/A) cleavage of synaptosomal-associated protein of 25 kD (SNAP-25). Although differences in sensitivity were apparent, SNAP-25 cleavage was detectable in neuronal cells from each of the 4 regions within 3 h at BoNT/A concentrations of 1 nM or lower. Co-incubation of chick neurons with BoNT/A and toxin-neutralizing antibodies inhibited SNAP-25 cleavage, demonstrating the utility of these cultures for the assay of BoNT/A antagonists. ( Journal of Biomolecular Screening 2007:370-377)

scholarly journals Intratracheal inoculation of AHc vaccine induces protection against aerosolized botulinum neurotoxin A challenge in mice

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Changjiao Gan ◽  
Wenbo Luo ◽  
Yunzhou Yu ◽  
Zhouguang Jiao ◽  
Sha Li ◽  
...  
Keyword(s):  
Bronchoalveolar Lavage ◽  
Clostridium Botulinum ◽  
Freeze Drying ◽  
Botulinum Neurotoxin ◽  
Secretory Iga ◽  
Immune Protection ◽  
Dry Powder ◽  
Botulinum Neurotoxin A ◽  
Spray Freeze Drying

AbstractBotulinum neurotoxin (BoNT), produced by Clostridium botulinum, is generally known to be the most poisonous of all biological toxins. In this study, we evaluate the protection conferred by intratracheal (i.t.) inoculation immunization with recombinant Hc subunit (AHc) vaccines against aerosolized BoNT/A intoxication. Three AHc vaccine formulations, i.e., conventional liquid, dry powder produced by spray freeze drying, and AHc dry powder reconstituted in water are prepared, and mice are immunized via i.t. inoculation or subcutaneous (s.c.) injection. Compared with s.c.-AHc-immunized mice, i.t.-AHc-immunized mice exhibit a slightly stronger protection against a challenge with 30,000× LD50 aerosolized BoNT/A. Of note, only i.t.-AHc induces a significantly higher level of toxin-neutralizing mucosal secretory IgA (SIgA) production in the bronchoalveolar lavage of mice. In conclusion, our study demonstrates that the immune protection conferred by the three formulations of AHc is comparable, while i.t. immunization of AHc is superior to s.c. immunization against aerosolized BoNT/A intoxication.

Sign in / Sign up

Export Citation Format

Share Document